We are live on ! Find out more
LIPO

Lipella Pharmaceuticals
LIPO

Delisted

LIPO was delisted on the 18th of June, 2025.

Back to rankings

4 hedge funds and large institutions have $59.5K invested in Lipella Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more funds holding

Funds holding: 4 → 4 (0)

0% more ownership

Funds ownership: 0.08% → 0.09% (+0%)

28% less capital invested

Capital invested by funds: $82.5K → $59.5K (-$23K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$6.7K
2
Wells Fargo
Wells Fargo
California
+$49

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$4.55K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$51.8K – – –
TRCT
2
Tower Research Capital (TRC)
New York
$7.38K +$6.7K +414 +206%
UBS Group
3
UBS Group
Switzerland
$258 -$4.55K -281 -93%
Wells Fargo
4
Wells Fargo
California
$42 +$49 +3 +300%

LIPO Hedge Fund Activity: Q3 2023 in Review

4 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q3 2023, worth a combined $59.5K — down 28% from $82.5K a quarter earlier.

Fund positioning in LIPO was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $6.7K. The largest seller was UBS Group, cutting an estimated $4.55K.

  • 4 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $59.5K of Lipella Pharmaceuticals stock for Q3 2023, down 28% quarter-over-quarter.
  • 0 funds opened new Lipella Pharmaceuticals positions in Q3 2023 and 0 closed out.
  • The largest Lipella Pharmaceuticals buyer in Q3 2023 was Tower Research Capital (TRC), an estimated $6.7K added.
  • The largest Lipella Pharmaceuticals seller in Q3 2023 was UBS Group, an estimated $4.55K sold.

Based on aggregated 13F filings for Q3 2023.